Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: Results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial

Journal of Clinical Oncology

Volumn 33, Issue 5, 2015, Pages 403-410

  Röllig, Christoph ^a   Bornhäuser, Martin ^a   Kramer, Michael ^a   Thiede, Christian ^a   Ho, Anthony D ^c   Krämer, Alwin ^c   Schäfer Eckart, Kerstin ^d   Wandt, Hannes ^a   Hänel, Mathias ^e   Einsele, Hermann ^f   Aulitzky, Walter E ^g   Schmitz, Norbert ^h   Berdel, Wolfgang E ⁱ   Stelljes, Matthias ⁱ   Müller Tidow, Carsten ^j   Krug, Utz ⁱ   Platzbecker, Uwe ^a   Wermke, Martin ^a   Baldus, Claudia D ^k   Krause, Stefan W ^l   Stölzel, Friedrich ^a   Von Bonin, Malte ^a   Schaich, Markus ^a   Serve, Hubert ^m   Schetelig, Johannes ^a,b,d   Ehninger, Gerhard ^a   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DKMS Nabelschnurblutbank   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d KLINIKUM NÜRNBERG   (Germany)

^e KLINIKUM CHEMNITZ   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g ROBERT BOSCH HOSPITAL   (Germany)

^h DEPARTMENT OF CARDIOLOGY   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^m UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; FLT3 LIGAND; MITOXANTRONE; NUCLEOPHOSMIN; THYMOCYTE ANTIBODY; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DONOR; DONOR VERSUS NO DONOR ANALYSIS; DRUG MEGADOSE; FEMALE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; INTERMEDIATE RISK PATIENT; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SIBLING; SIBLING DONOR; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SIBLINGS; TISSUE DONORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84922341259     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.4973     Document Type: Article

References (18)

1. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115:453-474, 2010
2. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005
3. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005
4. Cornelissen JJ, Gratwohl A, Schlenk RF, et al: The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach. Nat Rev Clin Oncol 9:579-590, 2012
5. Röllig C, Bornhäuser M, Thiede C, et al: Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: Evaluation of the proposed reporting system. J Clin Oncol 29:2758-2765, 2011
6. Kienast J, Beelen DW, Kolb HJ, et al: Allogeneic hematopoietic stem cell transplantation (Allo-SCT) versus conventional postremission therapy (PRT) for AML in first complete remission (CR1): A matched pairs analysis based on data of the AML Cooperative Group (AMLCG) 1999 trial. Blood 110 328, 2007 (abstr)
7. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358 1909-1918, 2008
8. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
9. Thiede C, Koch S, Creutzig E, et al: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Blood 107:4011-4020, 2006
10. Wheatley K, Gray R: Commentary: Mendelian randomization-An update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 33:15-17, 2004
11. Greiner J, Ono Y, Hofmann S, et al: Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 120:1282-1289, 2012
12. Greiner J, Schneider V, Schmitt M, et al: Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood 122:1087-1088, 2013
13. Hofmann S, Götz M, Schneider V, et al: Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation. J Clin Oncol 31:e44-e47, 2013
14. Burnett AK, Goldstone A, Hills RK, et al: Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 31:1293-1301, 2013
15. Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 109:3658-3666, 2007
16. Burnett AK, Milligan D, Prentice AG, et al: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114-1124, 2007
17. Shayegi N, Kramer M, Bornhäuser M, et al: The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 122:83-92, 2013
18. Krönke J, Schlenk RF, Jensen KO, et al: Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 29:2709-2716, 2011